CD109: A Promising Drug Target and Biomarker (G135228)
![Review Report on CD109 Target / Biomarker](https://silexon.ai/img/target-biomarker-review.jpg?a=1)
![Content of Review Report on CD109 Target / Biomarker](https://silexon.ai/img/target-biomarker-review-content.jpg?a=2)
CD109: A Promising Drug Target and Biomarker
Introduction
CD109 is a protein that is expressed in various tissues of the human body, including the skin, lungs, heart, and kidneys. It is a member of the intercellular adhesion molecule (ICAM) family and is involved in several physiological processes, including cell adhesion , migration, and invasion. CD109 has also been implicated in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, CD109 has emerged as a promising drug target and biomarker.
CD109 functions as a receptor for several different signaling pathways, including TGF-β, NF-kappa-B, and integrins. It is involved in the regulation of cell proliferation, differentiation, and survival, and its expression has been associated with several diseases, including cancer , neurodegenerative diseases, and autoimmune disorders.
CD109 as a drug target
CD109 has been identified as a potential drug target due to its involvement in several disease processes. For example, studies have shown that CD109 is overexpressed in various types of cancer, including breast, lung, and colon cancer. Additionally, CD109 has been shown to promote the growth and survival of cancer cells in cell culture and animal models.
CD109 has also been shown to play a role in neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Studies have shown that CD109 is overexpressed in the brains of individuals with these conditions, and that inhibiting CD109 may be a potential treatment approach.
CD109 has also been implicated in autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. Studies have shown that CD109 is overexpressed in the tissues of individuals with these conditions, and that inhibiting CD109 may be a potential treatment approach.
CD109 as a biomarker
CD109 has also been used as a biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that elevated CD109 levels can be used as a marker for cancer, and that inhibiting CD109 may be a potential cancer treatment approach.
In neurodegenerative diseases, CD109 has been used as a biomarker to monitor the effectiveness of drugs. For example, studies have shown that the levels of CD109 can be used to monitor the progression of Alzheimer's disease, and that inhibiting CD109 may be a potential treatment approach.
In autoimmune disorders, CD109 has been used as a biomarker to monitor the effectiveness of drugs. For example, studies have shown that the levels of CD109 can be used to monitor the progression of rheumatoid arthritis, and that inhibiting CD109 may be a potential treatment approach.
Conclusion
CD109 is a protein that is involved in several physiological processes and has been implicated in several diseases. As a result, CD109 has emerged as a promising drug target and biomarker. Further research is needed to fully understand the role of CD109 in disease and to develop effective treatments.
Protein Name: CD109 Molecule
Functions: Modulates negatively TGFB1 signaling in keratinocytes
The "CD109 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD109 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1